Logo image
Advances in the pathogenesis and treatment of IBD
Journal article   Open access   Peer reviewed

Advances in the pathogenesis and treatment of IBD

Nicholas A Braus and David E Elliott
Clinical immunology (Orlando, Fla.), Vol.132(1), pp.1-9
2009
DOI: 10.1016/j.clim.2009.02.006
PMID: 19321388
url
https://doi.org/10.1016/j.clim.2009.02.006View
Published (Version of record) Open Access

Abstract

Crohn's disease and ulcerative colitis are chronic remitting and relapsing inflammatory bowel diseases. We present a typical case of Crohn's disease in a young woman and discuss potential treatment options. Crohn's disease and ulcerative colitis likely result from interaction of multiple genetic and environmental risk and protective factors. Both are diseases ultimately caused by immune dysregulation. Medical therapy is with mesalamine compounds, corticosteroids, immunomodulators and/or biologics that target TNFα signaling or α4-integrin-mediated trafficking. Investigational agents include those targeted against other cytokines and costimulatory molecules or designed to promote immune regulation such as exposure to helminths which is a focus of this review.
Inflammatory bowel disease T lymphocytes Interleukin 4 TGF-beta IFN-gamma Interleukin 10 Crohn's disease Helminths Interleukin 17 Ulcerative colitis

Details

Metrics

Logo image